$17.08 -0.09 (%) Theravance Inc - NASDAQ

Oct. 24, 2014 | 04:00 PM

Partner Headlines

  1. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga | Oct. 20, 2014 | 16:58PM EST
  2. Data Published on Anoro(R) Ellipta(R) Demonstrate Improved Lung Function Compared to Tiotropium

    GuruFocus | Oct. 17, 2014 | 12:03PM EST
  3. Drug M&A Boom Driven By Long-Term Trends: PwC

    IBD | Sep. 3, 2014 | 16:22PM EST
  4. Barron's Recap: Ready To Wear?

    Benzinga | Jul. 27, 2014 | 21:02PM EST
  5. UPDATE: Bank Of America Downgrades Theravance As Pricing Headwinds Continue

    Benzinga | Jul. 24, 2014 | 08:10AM EST
  6. UPDATE: Morgan Stanley Reiterates On Theravance As Slow Trends Weigh On Value

    Benzinga | Jul. 21, 2014 | 11:09AM EST
  7. Theravance, Inc. Appoints Theodore J. Witek, Jr. As Senior VP, Corporate Partnerships, Clinical And Medical Affairs

    Benzinga | Jul. 2, 2014 | 16:07PM EST
  8. UPDATE: Stifel Downgrades Theravance Following Post-Split Accretion

    Benzinga | Jun. 12, 2014 | 07:49AM EST
  9. Benzinga's Top Downgrades

    Benzinga | Jun. 12, 2014 | 07:49AM EST
  10. UPDATE: Glaxo, Theravance Report Positive Data from Two Studies Considering Efficacy, Safety of Incruse(TM) Ellipta(R) Plus Relvar(R)/Breo(R) Ellipta(R) for COPD

    Benzinga | Jun. 11, 2014 | 07:44AM EST
  11. Theravance Announces Positive Results From a Phase 2 Study of TD-9855 in Patients With Fibromyalgia

    Benzinga | Apr. 30, 2014 | 16:26PM EST
  12. Theravance Announces Initiation of Phase 2b Study With TD-4208, an Investigational LAMA for the Treatment of COPD

    Benzinga | Apr. 10, 2014 | 16:09PM EST
  13. Glaxo's COPD Drug Gets European Green Light

    FoxBusiness | Feb. 20, 2014 | 09:41AM EST
  14. Morgan Stanley Expects Theravance to Continue to Underperform Following 4Q Earnings

    Benzinga | Feb. 7, 2014 | 09:28AM EST
  15. Top 2013 Drug Approvals: Pharma Stocks

    YCharts | Jan. 16, 2014 | 09:23AM EST
  16. Positive data for asthma drug

    IBD | Dec. 6, 2013 | 18:39PM EST
  17. Theravance, Glaxo COPD Drug Does Well In Asthma

    IBD | Dec. 6, 2013 | 12:24PM EST
  18. Seth Klarman Buys Micron Technology, Theravance, PBF Energy, Sells BP, AIG, Yamana Gold

    GuruFocus | Nov. 13, 2013 | 18:56PM EST
  19. GlaxoSmithKline

    IBD | Sep. 20, 2013 | 18:44PM EST
  20. US Stock Futures Signal Flat Start On Wall Street

    Benzinga | Sep. 20, 2013 | 07:16AM EST
  21. Relvar Ellipta Approved in Japan for Treatment of Asthma

    Benzinga | Sep. 20, 2013 | 06:21AM EST
  22. Glaxo, Theravance Confirm Positive CHMP Opinion for Relvar Ellipta

    Benzinga | Sep. 19, 2013 | 13:32PM EST
  23. Glaxo, Theravance Confirms FDA Panel Has Recommended Approval for UMEC/VI 62.5/25mcg Dose for COPD

    Benzinga | Sep. 10, 2013 | 15:55PM EST
  24. Theravance Reports Results from Phase 2B Study 0091 with TD-4208 for COPD, Says Met Primary Efficacy Endpoint

    Benzinga | Sep. 4, 2013 | 17:11PM EST
  25. Missed Klarman’s 47% Gainer? His Other Value Pick

    YCharts | Aug. 26, 2013 | 11:04AM EST
  26. Seth Klarman's Top 5 Second Quarter Holdings

    GuruFocus | Aug. 14, 2013 | 19:54PM EST
  27. Perrigo-Elan Merger Creates Unlikely Pharma Union

    IBD | Jul. 29, 2013 | 17:21PM EST
  28. UPDATE: Stifel Nicolaus Cuts PT to $37 on Theravance Ahead of March PADAC Meeting

    Benzinga | Feb. 13, 2013 | 05:41AM EST
  29. Theravance to Offer $250 Million Convertible Subordinated Notes Due 2023

    Benzinga | Jan. 16, 2013 | 09:24AM EST
  30. Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN

    GuruFocus | Jan. 7, 2013 | 04:34AM EST
  31. Theravance Confirms Favorable Ruling from FDA Panel on VIBATIV

    Benzinga | Nov. 29, 2012 | 10:17AM EST
  32. Theravance Offers FDA Briefing Documents for Panel Meeting on VIBATIV(R)

    Benzinga | Nov. 27, 2012 | 01:43AM EST
  33. Theravance Enters Agreement With Alfa Wassermann Worth Up To $53.5M

    Benzinga | Oct. 2, 2012 | 10:09AM EST
  34. The Baupost Group's Favorite Stocks

    Benzinga | Sep. 5, 2012 | 08:26AM EST
  35. Theravance Inc. (THRX) Sr VP, CFO Michael W Aguiar sells 24,682 Shares

    GuruFocus | Aug. 28, 2012 | 17:00PM EST
  36. GSK and Theravance Announce Completion of the Phase III Programme for Once-Daily LAMA/LABA (UMEC/VI) in COPD

    Benzinga | Aug. 24, 2012 | 01:05AM EST
  37. Weekly CFO Sells Highlight: SWN, BECN, NSIT, HOLX, QLTI, THRX

    GuruFocus | Aug. 13, 2012 | 14:19PM EST
  38. Theravance Inc. (THRX) Sr VP, CFO Michael W Aguiar sells 60,000 Shares

    GuruFocus | Aug. 9, 2012 | 16:21PM EST
  39. Theravance Inc. (THRX) CEO Rick E Winningham sells 75,749 Shares

    GuruFocus | Aug. 7, 2012 | 16:23PM EST
  40. A Peek Into The Market Before The Trading Starts

    Benzinga | Jul. 13, 2012 | 01:24AM EST
  41. GSK and Theravance Announce Regulatory Submissions for FF/VI in the US and Europe

    Benzinga | Jul. 13, 2012 | 01:01AM EST
  42. Target, Amgen Among Stocks Hitting 52-Week Highs Wednesday

    FoxBusiness | Jul. 11, 2012 | 06:33AM EST
  43. Dendreon, Pharmacyclics and Other Biotech Takeover Targets

    Benzinga | Jul. 10, 2012 | 08:07AM EST
  44. Merck &, Questcor Pharmaceuticals, Other Stocks Hit 52-Week Highs Monday

    FoxBusiness | Jul. 9, 2012 | 06:33AM EST
  45. Health Care Sector Wrap

    FoxBusiness | Jul. 3, 2012 | 10:35AM EST
  46. Health Care Sector Wrap

    FoxBusiness | Jul. 2, 2012 | 10:51AM EST
  47. GSK and Theravance Announce Positive Results From Four Pivotal Phase III Studies for Once-Daily LAMA/LABA (UMEC/VI) in COPD

    Benzinga | Jul. 2, 2012 | 02:24AM EST
  48. Theravance Inc. Reports Operating Results (10-K)

    GuruFocus | Feb. 27, 2012 | 10:14AM EST
  49. UPDATE: Morgan Stanley Initiates Underweight, $12 PT on Theravance

    Benzinga | Jan. 31, 2012 | 00:35AM EST
  50. Morgan Stanley Initiates Theravance at Underweight

    Benzinga | Jan. 30, 2012 | 23:11PM EST
Trading Center